News >

Therapeutic Challenges Continue to Emerge in Myelofibrosis

Nichole Tucker
Published: Wednesday, Aug 28, 2019

James K. McCloskey II, MD, interim chief, Division of Leukemia, John Theurer Cancer Center

James K. McCloskey II, MD

The optimal agents for high-risk and low-risk patients with myelofibrosis have yet to be identified. For low-risk patients, no drug has shown a significant improvement in overall survival; in high-risk disease, standard regimens generate fewer responses as patients typically present with a declining performance status.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x